Understanding how a new molecule can stop coronavirus infections
Developing Lectins as Inhibitors of Coronavirus Spike Proteins
This research explores how a special molecule called BOA can block the coronavirus from entering human cells, aiming to find new ways to fight infections like COVID-19.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-11364800 on NIH RePORTER |
What this research studies
The SARS-CoV2 virus, which causes COVID-19, enters our cells using its Spike protein. This protein has sugar molecules on its surface that help it attach to our cells. This project focuses on a new antiviral molecule, BOA, that has shown promise in binding to these sugar molecules on the Spike protein. By understanding exactly how BOA stops the virus from getting into cells, researchers hope to develop new treatments. The team will also test BOA against new coronavirus variants to see if it can still be effective.
Who could benefit from this research
Good fit: This foundational laboratory research does not directly involve patient participation, but future clinical trials stemming from this work would seek individuals with or at risk for coronavirus infections.
Not a fit: Patients not affected by coronavirus infections would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new medications that prevent or treat coronavirus infections by stopping the virus from entering our cells.
How similar studies have performed: The novel antiviral molecule BOA has already shown some success in laboratory settings by binding to the Spike protein and inhibiting viral entry.
Where this research is happening
La Jolla, United States
- University of California, San Diego — La Jolla, United States (Active)
Researchers
- Principal investigator: Guseman, Alex Joseph — University of California, San Diego
- Study coordinator: Guseman, Alex Joseph
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.